• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Edgewise

Edgewise Therapeutics

A Movement in Muscle

  • Clinical Trials
  • Careers
  • Investors & News
  • Company
    • Company Overview
    • Leadership Team
    • Careers
    • Contact Us

    We are dedicated to transforming cardiovascular muscle diseases.

    Learn More

  • Science
    • Pipeline
    • EDG-7500
    • EDG-15400
    • Clinical Trials
    • Posters & Presentations

    All of us at Edgewise are committed to developing new medicines for people facing serious cardiovascular diseases with unmet medical needs.

    Explore our Pipeline

  • Disease Areas
    • Cardiovascular Diseases
    • Muscular Dystrophy & Sevasemten

    Servier Acquires Our Muscular Dystrophy Program

    Following the close of our transaction with Servier, Edgewise’s muscular dystrophy business, including sevasemten, is now part of Servier. Servier’s global capabilities and commitment to neuromuscular diseases position it to advance sevasemten and continue supporting the patient and advocacy communities we have been privileged to serve.

    Edgewise is now focused exclusively on advancing high-impact therapies for people living with serious cardiovascular diseases.

    Learn more

  • Patients & Families
  • Investors & News
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Governance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts
HomeScienceEDG-7500

EDG-7500

Targeting HCM

We are developing EDG-7500, a selective cardiac sarcomere modulator, with the aim to slow early contraction velocity and address impaired cardiac relaxation associated with symptomatic hypertrophic cardiomyopathy (HCM).

Hypertrophic Cardiomyopathy

Two major forms of HCM include obstructive (oHCM) and nonobstructive (nHCM), each leading to impaired cardiac performance. In oHCM, as the left ventricle (LV) contracts (systole) to eject oxygenated blood from the heart into systemic circulation, the mitral valve makes physical contact with the hypertrophied septal wall. This contact underlies the basis of the obstructed ejection of blood through the LV outflow tract (LVOT) creating a pressure difference, or gradient (LVOT-G) between the LV cavity and systemic circulation.

In nHCM, the hypertrophy is more symmetrically distributed in the LV walls, therefore the patient does not develop LVOT obstruction nor pressure gradient. However due to LV hypertrophy and stiffness, LV relaxation is impaired and LV filling with blood (diastole) is significantly reduced.

Healthy Heart vs. Heart with HCM

Click to view more

About EDG-7500

Targeting the sarcomere

EDG-7500 is a novel oral, selective cardiac sarcomere modulator for the treatment of symptomatic HCM.

Potential to address symptomatic obstructive and nonobstructive HCM

In symptomatic obstructive and nonobstructive HCM, treatment with EDG-7500 is targeted to improve cardiac relaxation and filling without significant impairment of systolic performance.

View our EDG-7500 presentations

Designed to address unmet needs in HCM

Preclinical and preliminary clinical data support EDG-7500 having the potential for significant efficacy, measured by gradient response, while preserving safety, reflected by minimal changes in ejection fraction. EDG-7500 is currently in clinical trials in symptomatic oHCM and nHCM.

Learn more about EDG-7500 clinical trials

EDG-7500 is an investigational therapy that has not been approved for use in HCM by any regulatory agency, as its safety and effectiveness have not been established for the treatment of this disease.

Footer

Edgewise Therapeutics
  • Company
  • Science
  • Disease Areas
  • Patients & Families
  • Investors & News

In the Clinic

We are advancing novel precision therapeutics for serious cardiovascular disease.

Explore our pipeline

2026 © Copyright. Edgewise Therapeutics. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
Facebook X, formally Twitter LinkedIn Instagram YouTube
logo
  • Company
    • Leadership Team
    • Careers
    • Contact Us
  • Science
    • Pipeline
    • EDG-7500
    • EDG-15400
    • Clinical Trials
    • Posters & Presentations
  • Disease Areas
    • Cardiovascular Diseases
    • Muscular Dystrophy & Sevasemten
  • Patients & Families
  • Investors & Media
    • Corporate Profile
    • News
    • Events & Presentations
    • Analyst Coverage
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
    • Financials
      • Quarterly Results
      • SEC Filings
    • Goverance
      • Governance Documents
      • Committee Composition
    • Resources
      • Investor FAQs
      • Investor Email Alerts
      • Investor Contacts